Section 1: Modelling Patient Variants Using CRISPR-Cas9 in C. elegans

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/20

encourage image

There's no tags or description

Looks like no tags are added yet.

Last updated 3:18 PM on 5/12/26
Name
Mastery
Learn
Test
Matching
Spaced
Call with Kai

No analytics yet

Send a link to your students to track their progress

21 Terms

1
New cards
2
New cards

What is a Variant of Uncertain Significance (VUS)?

Mostly missense variants that cannot be classified as pathogenic or benign, making them not clinically actionable.

3
New cards

What percentage of missense variants in ClinVar are VUS?

~58% of 207,000+ reported missense variants.

4
New cards

What is the clinical impact of a VUS designation?

Patients cannot join gene therapy trials or receive targeted treatments; it is a dead end for clinical action.

5
New cards

How does C. elegans help solve the VUS challenge?

It provides functional evidence to reclassify VUS as "likely pathogenic" or "likely benign," bridging genomic sequencing to clinical diagnosis.

6
New cards

How fast can new worm strains with patient mutations be generated using CRISPR-Cas9?

In 2–3 weeks.

7
New cards

What are the two requirements for successfully modelling a human VUS in C. elegans?

① Conservation of the mutated residue at the orthologous position; ② Shared biological function between species.

8
New cards

What disease was modelled in the Lange et al. (2021) case study?

Joubert Syndrome (JBTS), a ciliopathy with "molar tooth sign" brain malformation.

9
New cards

What were the two patient mutations in human B9D2 studied by Lange et al.?

P74S (in the B9 domain) and G155S (in the C-terminal region).

10
New cards

What is the worm orthologue of human B9D2?

mksr-2 (encoding MKSR-2 protein), with 63.4% similarity to human B9D2.

11
New cards

Why did Lange et al. use endogenous tagging with mNeonGreen?

To avoid overexpression artefacts by knocking the tag in at the 5' end of the endogenous mksr-2 locus.

12
New cards

What genotype was created to mimic the patient's biallelic state?

Compound heterozygotes (P74S/G155S), plus carrier controls (P74S/+, G155S/+).

13
New cards

What did super-resolution microscopy reveal about the two variants?

G155S caused severe reduction and disorganized Transition Zone (TZ) distribution; P74S caused a milder reduction.

14
New cards

Why did the study use an nphp-4(Δ) sensitized background?

Because single TZ mutants often appear normal; the sensitized background makes ciliary structure defects visible.

15
New cards

What behavioural assays were used to assess variant severity?

Roaming (food foraging) and osmotic avoidance (high osmolarity barriers).

16
New cards

Which variant showed a stronger defect in osmotic sensing?

G155S.

17
New cards

How was ciliary gating (barrier integrity) tested?

By testing for leakage of proteins normally excluded from the cilium (RPI-2, TRAM-1) across the transition zone.

18
New cards

What was the gating result for P74S vs. G155S?

G155S disrupted gating (leakage present); P74S did NOT cause leakage.

19
New cards

What was the final pathogenic classification from the study?

Both P74S and G155S are pathogenic, reclassifying VUS as clinically actionable.

20
New cards

What new biological insight came from these hypomorphic alleles?

They revealed close functional and spatial association between MKSR-2 and MKS-2 at the transition zone.

21
New cards

What is the mnemonic for the gating assay result comparing the two variants?

G155S = Gate broken (leakage present); P74S = Permission denied (no leakage, gate intac